Objective: To evaluate the clinical efficacy and safety of novel ZelanteDVT™ catheter rheolytic thrombectomy in the single-session endovascular management of subacute deep venous thrombosis (DVT).
Methods: A retrospective study was performed on 31 patients with subacute DVT who underwent ZelanteDVT™ catheter rheolytic thrombectomy. Procedure data, associated complications, and venous patency score were recorded. The deep venous patency and post-thrombotic syndrome (PTS) rate were assessed in all patients during follow-up visits.
Results: After procedure, 19.4% (6/31) patients improved to grade III thrombus removal, while the remaining patients improved to grade II. Significant iliac vein compression syndrome was identified in 54.8% (17/31) patients, and 82.4% (14/17) of them received stent implantation. No serious procedure-related complications occurred. The median follow-up time was 13 months. The primary patency rate at 12 months was 83.87%, and the incidence of PTS was 19.35%.
Conclusion: This novel rheological thrombectomy catheter seems to have a promising application prospect for single-session treatment of subacute DVT.
Keywords: ZelanteDVT™ catheter; post-thrombotic syndrome; rheolytic thrombectomy; subacute deep venous thrombosis; thrombus clearance rate.